AGP
CTMX icon

Aspire Growth Partners’s CytomX Therapeutics CTMX Stock Holding History

Aspire Growth Partners’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Hold
102,254
– – 0.22% 83
2026
Q1 		$481K Hold
102,254
– – 0.33% 69
2025
Q4 		$436K Hold
102,254
– – 0.3% 75
2025
Q3 		$326K Hold
102,254
– – 0.24% 89
2025
Q2 		$232K Buy
102,254
+10,000
+11% +$16.1K 0.19% 104
2025
Q1 		$88.6K Buy
92,254
+51,474
+126% +$39.9K 0.08% 113
2024
Q4 		$42K Buy
+40,780
New +$43.9K 0.04% 99

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Aspire Growth Partners's CTMX Position: Q2 2026 in Review

Aspire Growth Partners held its CytomX Therapeutics (CTMX) position steady in Q2 2026 at 102,254 shares worth $383K. The position accounts for 0.22% of the portfolio, ranked #83.

Aspire Growth Partners first reported a position in CTMX in Q4 2024 and has held it in 7 quarters since. The position peaked at $481K in Q1 2026. 179 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

  • Aspire Growth Partners held 102,254 shares of CytomX Therapeutics worth $383K as of Q2 2026.
  • Aspire Growth Partners left its CytomX Therapeutics share count unchanged in Q2 2026.
  • CytomX Therapeutics made up 0.22% of Aspire Growth Partners's portfolio in Q2 2026, its #83 holding.
  • Aspire Growth Partners first reported a position in CytomX Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Aspire Growth Partners's CytomX Therapeutics position peaked at $481K in Q1 2026.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Aspire Growth Partners's 13F filing for Q2 2026, filed 29 Jul 2026.